Is Renoprotection Real for Patients with Hyperuricemia?
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Number of patients with progressive chronic kidney disease (CKD) is increasing all over the world. One of the risk factors for CKD development and progression is increased serum uric acid (sUA) level. Possibly, control of hyperurcemia with urate lowering therapy drugs can slow the decline in kidney function.
The objective: to determine efficacy and safety of allopurinol and febuxostat in treatment of patients with CKD and hyperurcemia to reduce the sUA level and analyze its influence on glomerular filtration rate (GFR).
Materials and methods. The study included 45 CKD patients (stages 3b-5) without other severe/decompensated diseases and contraindications to the allopurinol/febuxostat. All patients underwent a comprehensive clinical and laboratory examination, and were divided into the study groups: Group I (28 patients, 61.3±3.2 y.o., CKD3b-12, CKD4-10, on hemodialysis-6 patients) received febuxostat, Group II (24 patients, 60.7Ѓ}4.1 y.o., CKD3b-9, CKD4-10, on hemodialysis – 5 patients) took allopurinol.
Results. Achievement of the target level of sUA was significantly often registered in Group I: after 1 month – in 45.5% (in group II – in 15.9%, p<0.001); after 3 months – in 67.5% (in group II – 21.2% p<0.01); after 6 months, these figures were 90% and 37.1%, respectively (p<0.01). sUA level <300 μmol/l was accompanied by significant positive GFR changes in group I patients; in group II there was a gradual progression of GFR deterioration in 31.8% of patients.
Conclusions. In patients with pre-dialysis stages of CKD febuxostat demonstrates renoprotective abilities. Use of febuxostat in patients with CKD stage 3b-4 and in patients on hemodialysis is safe and more effective for target sUA level achievement than the use of allopurinol.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Centers for Disease Control and Prevention. Chronic kidney disease in US [Internet]. US: Department of Health & Human Services; 2021. Available from: https://www.cdc.gov/kidneydisease/basics.html
Kuma A, Mafune K, Uchino B, Ochiai Y, Enta K, Kato A. Alteration of normal level of serum urate may contribute to decrease in estimated glomerular filtration rate decline in healthy Japanese men. Ren Fail. 2021;43(1):1408–15. doi:10.1080/0886022X.2021.1988969.
Capuano V, Marchese F, Capuano R, Torre S, Iannone AG, Capuano E, et al. Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med. 2017;18(3):159–64. doi: 10.2459/JCM.0000000000000347.
Siqueira JH, Mill JG, Velasquez-Melendez G, Moreira AD, Barreto SM, Benseсor IM, et al. Sugar-Sweetened Soft Drinks and Fructose Consumption Are Associated with Hyperuricemia: Cross-Sectional Analysis from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Nutr. 2018;10 (8):981. doi: 10.3390/nu10080981.
Li L, Yang C, Zhao Y, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analyse based on observational cohort studies. BMC Nephrol. 2014;15:122. doi: 10.1186/1471-2369-15-122.
Sharma G, Dubey A, Nolkha N, Singh JA. Hyperuricemia, urate-lowering therapy, and kidney outcomes; a systematic review and meta-analysis. Ther Adv Musculoscelet Dis. 2021;13:1–21. doi: 10.1177/1759720X211016661.
Yu P, Huang Li, Wang Z, Meng X, Yu X. The association of serum uric acid with beta-cell function and insulin resistance in non-diabetic individuals: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:2673–82. doi: 10.2147/DMSO.S312489.
Usama AA, Sharaf ED, Salem MM. Uric acid in the pathogenesis of metabolic, renal and cardiovascular diseases; a review. J of Adv Res. 2017;8(5):537–48. doi: 10.1016/j.jare.2016.11.004.
Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis. 2014;232(2):265–70. doi: 10.1016/j.atherosclerosis.2013.11.051.
Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. JASN. 2008;19(12):2407–13. doi: 10.1681/ASN.2008010080.
Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. Uric acid and incident of kidney disease in community. JASN. 2008;19(6):1204–11. doi: 10.1681/ASN.2007101075.
Skoczynska M, Chowaniec M, Szymczak A, Langner-Hetmanczuk A, Maciążek-Chyra B, Wiland P. Pathophysiology of hyperuricemia and its clinical significance – a narrative review. 2020;58(5):312–23. doi: 10.5114/reum.2020.100140.
Stack A, Manolis AJ, Ritz E. Detrimental role of hyperuricemia on the cardio-reno-vascular system. Curr Med Res Opin. 2015;31(Suppl 2):21–6. doi: 10.1185/03007995.2015.1087984.
Badve SV, Pascoe EM, Biostat M, Boudville N, Brown FG, Casset A, et al. Effects of allopurinol on the Progression of Chronic Kidney Disease. N Eng J Med. 2020;382(26):2504–13. doi: 10.1056/NEJMoa1915833.
Liu X, Liu K, Sun Q, Wang Y, Meng J, Xu Z, et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with CKD and renal transplant recipients: a systemic review and meta-analysis. Exp Ther Med. 2018;16(3):1859–65. doi:10.3892/etm.2018.6367.
Lin TC, Hung LY, Chen Y-C, Wei-Cheng Lo, Lin CH, Tam K-W, et al. Effects of febuxostat on renal function in patients with chronic kidney disease. A systematic review and meta-analysis. Medicine. 2019;98(29):29(e16311). doi: 10.1097/MD.0000000000016311.
Keilstein JT, Pontremoli R, Burnier M. Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection. Curr Hypertens Rep. 2020;22(12):102. doi: 10.1007/s11906-020-01116-3.
Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . Int J Clin Pharmacol Ther. 2020;58(1):21–8. doi: 10.5414/CP203466.
Liu X, Wang H, Ma R, Shao L, Zhang W, Jiang W, et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol. 2019;23(3):362–70. doi: 10.1007/s10157-018-1652-5.
Lee JW, Lee KH. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019;51(3):467–73. doi: 10.1007/s11255-018-2051-2.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60. doi: 10.1002/acr.24180.
Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatol. 2017;56(7):1–20. doi: 10.1093/rheumatology/kex156.
Anderson IJ, Davis AM, Jan RH. Management of Gout. JAMA. 2021;326(24):2519–20.
Li Q, Li X, Wang J, Liu H, Kwong JS-W, Chen H, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. doi: 10.1136/bmjopen-2018-026677.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi: 10.1136/annrheumdis-2016-209707.
